Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals Inc. develops biotechnology drug candidates through a biology-centric discovery engine that combines disease biology and protein engineering. Company news has centered on clinical and regulatory updates for its pipeline, including NGM707, a dual ILT2/ILT4 antagonist antibody evaluated in advanced or metastatic solid tumors, and aldafermin development in primary sclerosing cholangitis and other rare-disease strategy discussions.
Recurring updates also include oncology conference presentations, clinical-data posters, operating and financial results, governance matters, capital-structure disclosures, shareholder voting matters and material agreements. Corporate-action news includes the completed cash tender offer by an affiliate of The Column Group for shares of NGM Bio not already held by affiliates and certain other stockholders.
NGM Biopharmaceuticals (NGM) announced promising results from its Phase 1b trial of NGM120, an antibody targeting GFRAL, for metastatic pancreatic cancer. The treatment was well tolerated with no dose-limiting toxicities. Among six evaluable patients, there was a 100% disease control rate, and the 12-month survival rate was 83.3%. Notably, three patients achieved partial responses lasting over 32 weeks, with one ongoing at 90 weeks. Further studies, including a Phase 2 trial, are planned to explore NGM120's efficacy in combination with gemcitabine and Nab-paclitaxel.
NGM Biopharmaceuticals reported encouraging preliminary results from its Phase 1a trial of NGM120, an antibody targeting GFRAL to treat advanced prostate cancer. The study showed good tolerability, with no dose-limiting toxicities. Notably, two out of five patients exhibited disease control, including one partial response at 62 weeks and PSA reductions. NGM is expanding its research with a Phase 1b cohort testing NGM120 in combination with hormone therapies for metastatic castration-resistant prostate cancer. Further details will be presented at the ESMO Annual Congress on September 11, 2022.
NGM Biopharmaceuticals announced that abstracts for NGM120 have been accepted for presentation at two major conferences: ESMO Annual Congress (September 9-13, 2022) and AACR Special Conference on Pancreatic Cancer (September 13-16, 2022). NGM120 is an antagonist antibody targeting GFRAL to inhibit GDF15 signaling, associated with poor prognosis in various cancers. Presentations will include initial results from Phase 1a and 1b trials focusing on advanced prostate and pancreatic cancer patients, respectively.
NGM Biopharmaceuticals has initiated multiple clinical trials, including Phase 1/1b for NGM438 and Phase 1b for NGM707, both in combination with KEYTRUDA for advanced solid tumors. The company reported a net loss of $46.5 million for Q2 2022, an increase from $36.7 million year-over-year. Collaboration revenue from Merck was notably lower at $8.3 million compared to $16.8 million in the same quarter last year, and is expected to remain diminished through March 2024. Cash and equivalents totaled $297.8 million, down from $366.3 million at year-end 2021.
NGM Biopharmaceuticals, Inc. (NGM) has announced a leadership transition as Siobhan Nolan Mangini assumes the additional role of President, while continuing as CFO. This change, effective July 1, 2022, reflects her significant impact since joining in 2020. David J. Woodhouse remains CEO, and William J. Rieflin will move from Executive Chairman to Chairman of the Board. The company aims for long-term growth through its diverse pipeline and operational leadership. Notably, Mangini previously raised over $170 million and facilitated a collaboration with Merck.
NGM Biopharmaceuticals will showcase its monoclonal antibody product candidate, NGM621, aimed at treating geographic atrophy, in the last part of the "Explorer Series" on June 29, 2022. This virtual event will feature insights from the research team and Dr. Charles Wykoff.
NGM621 targets complement C3, crucial for managing immune response. The webcast will be available on NGM Bio's website, with a recording accessible for one year post-event. NGM Bio focuses on transformative therapeutics across cancer, retinal diseases, and metabolic disorders.
NGM Biopharmaceuticals, Inc. (NGM) has announced that CEO David J. Woodhouse, Ph.D., will present a company overview and business update at two upcoming investor conferences. The presentations will take place at the Jefferies Healthcare Conference on June 9, 2022, at 8:30 am ET, and the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 12:20 pm ET. Live webcasts and replays will be available on NGM's website following the events. NGM focuses on developing innovative therapeutics across several areas, including cancer and metabolic diseases.
NGM Biopharmaceuticals, Inc. (NGM) will host the third virtual R&D event, part of its "Explorer Series," on May 31, 2022. This session will focus on NGM707, a dual ILT2/ILT4 antagonist antibody aimed at enhancing anti-tumor immunity by reprogramming myeloid cells. Presentations will feature NGM Bio’s R&D team and Dr. Marco Colonna from Washington University. The final session will cover NGM621, targeting complement C3 for geographic atrophy treatment. A live webcast will be available on NGM’s website, with a replay archived for one year.
NGM Biopharmaceuticals has initiated a Phase 1/1b clinical trial of NGM438, a LAIR1 antagonist antibody, targeting advanced solid tumors. This trial evaluates NGM438 as a monotherapy and in combination with Merck's KEYTRUDA. With this addition, all three of NGM Bio’s myeloid checkpoint inhibitors—NGM438, NGM707, and NGM831—are now in clinical development. The trial is set to enroll up to 80 patients across various cancer types, aimed at assessing safety, pharmacokinetics, and preliminary antitumor activity.
NGM Biopharmaceuticals, Inc. (NGM) has initiated a Phase 1/1b clinical trial for NGM831, a novel ILT3 antagonist antibody product candidate, as both a monotherapy and in combination with KEYTRUDA for advanced solid tumors. The company reported a net loss of $32.5 million for Q1 2022, compared to $27.5 million in Q1 2021. Related party revenue fell to $20.9 million from $21.6 million year-over-year. NGM also received Fast Track designation from the FDA for NGM621, aimed at treating geographic atrophy. As of March 31, 2022, the company reported cash reserves of $329.8 million.